Gallant and MWI Animal Health Forge Landmark Partnership to Launch First FDA-Conditionally Approved Off-the-Shelf Stem Cell Therapy for Pets

In February 2026, the field of veterinary medicine witnessed two major developments.

About two weeks ago, global healthcare giant Cencora and Covetrus entered into a definitive agreement to merge Cencora’s MWI Animal Health with Covetrus, valuing MWI at $3.5 billion. The objective of this transaction is clear: to combine MWI’s distribution capabilities in the pet healthcare sector with Covetrus’s technology-driven solutions, creating a “comprehensive animal health platform.”

Innovative drugs are also gaining momentum. Just as the industry was still digesting the largest-ever acquisition of a U.S. animal health company, MWI Animal Health struck again on February 27 by entering into a landmark fulfillment agreement with Gallant, an animal health biotechnology firm. Together, they will build the first ultra-low temperature (-80°C) cold chain system for the pet medication sector, paving the “last mile” for Gallant’s upcoming innovative stem cell product.

To understand the significance of this collaboration, it is necessary to first examine Gallant’s product technology.

Gallant is a clinical-stage animal health biotechnology company headquartered in San Diego, with a core mission to leverage off-the-shelf stem cell therapies to treat diseases in pet cats and dogs at their source. Unlike traditional veterinary medicine’s approach of “symptom management,” Gallant focuses on disease modification, intervening at the root level to alter the progression of inflammatory and degenerative conditions.

The most notable product in the company’s pipeline is sonruvetcel injectable suspension. This is a potential first-in-class, uterus-derived allogeneic mesenchymal stromal cell (MSC) therapy specifically targeting refractory feline chronic gingivostomatitis (rFCGS). Refractory feline chronic gingivostomatitis (FCGS) is a severe oral disease characterized by an exaggerated immune response to dental plaque, with symptoms including persistent halitosis, hypersalivation, and difficulty eating. The most effective and currently recommended treatment is extraction of most or all teeth. However, due to the lack of effective therapeutic options, many cats are ultimately euthanized. Gallant’s stem cell therapy offers hope for this “underserved population of affected cats.”

Notably, Gallant completed two key technical components for the FDA in 2025: the Reasonable Expectation of Effectiveness (RXE) in September and the Target Animal Safety (TAS) study in early November.

In September 2025, Gallant announced significant progress in the FDA’s conditional approval pathway for its leading therapy targeting refractory feline chronic gingivostomatitis (rFCGS), with the FDA Center for Veterinary Medicine (FDA-CVM) issuing a letter confirming “technical completion of reasonable expectation of effectiveness (RXE).” A pivotal clinical trial published in a peer-reviewed journal demonstrated that over 75% of treated cats showed clinically relevant improvements in quality of life within 90 days, nearly half exhibited measurable improvement in oral lesions, and no serious treatment-related adverse events were observed.

In November 2025, Gallant achieved another milestone as the FDA-CVM issued a letter confirming the “completion of the technical section for Target Animal Safety (TAS),” acknowledging that its data supported the 365-day safety requirement for the cell therapy. Notably, this safety study was conducted not in healthy animals but in cats affected by rFCGS, thereby establishing both short-term and long-term safety.

The data are derived from an open-label study, which lacked a control group and had a small sample size. Nevertheless, in the indication of refractory FCGS, the improvement signals were clear and consistent in direction. It can be said that regulatory authorities have identified structured elements suggesting that the “development pathway may be viable” for this product: controllable manufacturing, interpretable efficacy, and long-term traceability of safety.

In fact, the UMSC (uterus-derived mesenchymal stromal cells) that Gallant focuses on is not a revolutionary technology. Its key advantages lie in the high consistency of uterus-derived cells, lower ethical concerns, and suitability for scalable manufacturing. By comparison, investment firms, the industry, and regulators place greater emphasis on its ability to make animal cell therapies more akin to “drugs” rather than “technical services.”

In recent years, Gallant has unusually concentrated its resources on manufacturing and the Chemistry, Manufacturing, and Controls (CMC) framework. Gallant’s cells are sourced from healthy, specific pathogen-free, FDA-registered feline donors and manufactured in compliance with current Good Manufacturing Practices (cGMP). This approach marks a significant departure from the traditional “clinic-manufactured, fresh-use” model prevalent in veterinary stem cell therapies. Overall, Gallant has adopted a pharmaceutical-grade approach akin to human drug development, which aligns precisely with the FDA Center for Veterinary Medicine’s (FDA-CVM) strategic shift: only products that can be clearly understood within the regulatory framework are qualified to become the first approved cell therapy.

With the completion of its two core modules, RXE and TAS, Gallant’s sonruvetcel has overcome the major technical hurdles preceding FDA conditional approval and is expected to receive such approval in 2026. Once approved, it will be the first off-the-shelf stem cell therapy for veterinary use to gain FDA regulatory clearance.

Indeed, breakthrough science is only half the story.

“Breakthrough science only matters when we can safely and reliably put it into the hands of veterinary professionals,” said Linda Black, DVM, CEO of Gallant, commenting on the partnership. This highlights one of the major bottlenecks in translating regenerative medicine from the laboratory to clinical practice: ultra-low-temperature cold chain logistics.

Gallant’s stem cell therapy requires storage and transportation at -80°C. While mature solutions for this may already exist in human pharmaceuticals, it remains a gap in the field of pet medicine or veterinary science. There are tens of thousands of veterinary clinics across the United States, widely distributed and varying in size, with the vast majority lacking the hardware infrastructure and operational experience to handle ultra-low temperature products at -80°C. If the delivery issue cannot be resolved, even with FDA approval, this new drug would remain confined to freezers in distribution centers, failing to truly benefit those in need.

This is precisely where MWI Animal Health comes into play, and it constitutes the strategic core of this collaboration.

Under the agreement, MWI will develop and deploy a scalable “ultra-cold fulfillment model.” Leveraging its distribution center in Edwardsville, Kansas, the system will support nationwide supply through overnight shipping, ensuring coverage of non-contiguous U.S. markets, including Alaska, Hawaii, and Puerto Rico.

Two weeks ago, Cencora, the parent company of MWI, completed a major transaction: merging MWI Animal Health with Covetrus to create an integrated animal health platform, valuing MWI at $3.5 billion.

Viewing these two developments together, MWI’s strategic trajectory becomes clear.

MWI’s traditional strength lies in distribution. However, through its merger with Covetrus, it is integrating technology-driven solutions and evolving into a platform capable of delivering value-added services. The establishment of an ultra-low-temperature cold chain in partnership with Gallant exemplifies this capability, ensuring integrity throughout the transportation process while creating a new service model.

On the other hand, MWI values not only Gallant’s inaugural product but also its underlying technology platform and product pipeline. Both parties anticipate that this collaboration will serve as a model, paving the way for Gallant’s broader pipeline of disease-modifying therapies targeting inflammatory and degenerative conditions in pets. Once sonruvetcel receives regulatory approval, a series of subsequent products for canine and feline osteoarthritis, feline chronic kidney disease, and canine atopic dermatitis will rapidly enter the market via this established ultra-cold chain logistics infrastructure.